Evaluation of neurapheresis therapy in vitro: a novel approach for the treatment of leptomeningeal metastases.
Neurapheresis
VX2
leptomeningeal metastases
methotrexate
subarachnoid space
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
epublish
Résumé
Leptomeningeal metastases (LM), late-stage cancer when malignant cells migrate to the subarachnoid space (SAS), have an extremely poor prognosis. Current treatment regimens fall short in effectively reducing SAS tumor burden. Neurapheresis therapy is a novel approach employing filtration and enhanced circulation of the cerebrospinal fluid (CSF). Here, we examine the in vitro use of neurapheresis therapy as a novel, adjunctive treatment option for LM by filtering cells and augmenting the distribution of drugs that may have the potential to enhance the current clinical approach. Clinically relevant concentrations of VX2 carcinoma cells were suspended in artificial CSF. The neurapheresis system's ability to clear VX2 carcinoma cells was tested with and without the chemotherapeutic presence (methotrexate [MTX]). The VX2 cell concentration following each filtration cycle and the number of cycles required to reach the limit of detection were calculated. The ability of neurapheresis therapy to circulate, distribute, and maintain therapeutic levels of MTX was assessed using a cranial-spinal model of the SAS. The distribution of a 6 mg dose was monitored for 48 h. An MTX-specific ELISA measured drug concentration at ventricular, cervical, and lumbar sites in the model over time. In vitro filtration of VX2 cancer cells with neurapheresis therapy alone resulted in a 2.3-log reduction in cancer cell concentration in 7.5 h and a 2.4-log reduction in live-cancer cell concentration in 7.5 h when used with MTX. Cranial-spinal model experiments demonstrated the ability of neurapheresis therapy to enhance the circulation of MTX in CSF along the neuraxis. Neurapheresis has the potential to act as an adjunct therapy for LM patients and significantly improve the standard of care.
Sections du résumé
BACKGROUND
BACKGROUND
Leptomeningeal metastases (LM), late-stage cancer when malignant cells migrate to the subarachnoid space (SAS), have an extremely poor prognosis. Current treatment regimens fall short in effectively reducing SAS tumor burden. Neurapheresis therapy is a novel approach employing filtration and enhanced circulation of the cerebrospinal fluid (CSF). Here, we examine the in vitro use of neurapheresis therapy as a novel, adjunctive treatment option for LM by filtering cells and augmenting the distribution of drugs that may have the potential to enhance the current clinical approach.
METHODS
METHODS
Clinically relevant concentrations of VX2 carcinoma cells were suspended in artificial CSF. The neurapheresis system's ability to clear VX2 carcinoma cells was tested with and without the chemotherapeutic presence (methotrexate [MTX]). The VX2 cell concentration following each filtration cycle and the number of cycles required to reach the limit of detection were calculated. The ability of neurapheresis therapy to circulate, distribute, and maintain therapeutic levels of MTX was assessed using a cranial-spinal model of the SAS. The distribution of a 6 mg dose was monitored for 48 h. An MTX-specific ELISA measured drug concentration at ventricular, cervical, and lumbar sites in the model over time.
RESULTS
RESULTS
In vitro filtration of VX2 cancer cells with neurapheresis therapy alone resulted in a 2.3-log reduction in cancer cell concentration in 7.5 h and a 2.4-log reduction in live-cancer cell concentration in 7.5 h when used with MTX. Cranial-spinal model experiments demonstrated the ability of neurapheresis therapy to enhance the circulation of MTX in CSF along the neuraxis.
CONCLUSION
CONCLUSIONS
Neurapheresis has the potential to act as an adjunct therapy for LM patients and significantly improve the standard of care.
Identifiants
pubmed: 32642705
doi: 10.1093/noajnl/vdaa052
pii: vdaa052
pmc: PMC7236387
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdaa052Informations de copyright
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Surg Neurol Int. 2013 May 02;4(Suppl 4):S265-88
pubmed: 23717798
Am J Cancer Res. 2013 Apr 03;3(2):117-26
pubmed: 23593536
J Infect Dis. 2018 Aug 24;218(7):1147-1154
pubmed: 29788431
JAMA Oncol. 2019 May 1;5(5):703-709
pubmed: 30844036
Cancer. 2018 Jan 1;124(1):21-35
pubmed: 29165794
Eur J Cancer. 2004 Dec;40(18):2726-33
pubmed: 15571954
J Neurooncol. 2014 Sep;119(2):361-8
pubmed: 24942463
Oncologist. 2016 Dec;21(12):1471-1482
pubmed: 27496039
Oper Neurosurg (Hagerstown). 2019 May 1;16(5):E148-E153
pubmed: 29873785
Cancer Invest. 2005;23(2):145-54
pubmed: 15813508
Lancet Oncol. 2010 Sep;11(9):871-9
pubmed: 20598636
Neurosurg Clin N Am. 2011 Jan;22(1):67-78, vii
pubmed: 21109151
J Virol. 1985 Jul;55(1):246-50
pubmed: 2409299
Oncotarget. 2017 Aug 16;8(42):73312-73328
pubmed: 29069871
Ann Biomed Eng. 2011 Jan;39(1):484-96
pubmed: 20737291
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):537-43
pubmed: 26867883
J Clin Neurosci. 2015 Apr;22(4):632-7
pubmed: 25677875
Clin Pharmacokinet. 2005;44(1):1-31
pubmed: 15634030
Stroke. 2019 Sep;50(9):2558-2561
pubmed: 31345133
J Biomech. 2015 Jul 16;48(10):2144-54
pubmed: 25888012
J Korean Neurosurg Soc. 2012 Sep;52(3):193-9
pubmed: 23115660
Anesth Analg. 2012 Aug;115(2):386-94
pubmed: 22523420
Neuro Oncol. 2019 May 03;:
pubmed: 31051044
IEEE Trans Biomed Eng. 2010 Jun;57(6):1255-63
pubmed: 20142150
IEEE Trans Biomed Eng. 2005 Apr;52(4):557-65
pubmed: 15825857
Comput Biol Med. 2011 Feb;41(2):67-75
pubmed: 21215965
Oncol Lett. 2016 Aug;12(2):1301-1314
pubmed: 27446430
J Support Oncol. 2012 Mar-Apr;10(2):45-53
pubmed: 22005214